Literature DB >> 30217872

An Interleukin-1 Signature in Breast Cancer Treated with Interleukin-1 Receptor Blockade: Implications for Treating Cytokine Release Syndrome of Checkpoint Inhibitors.

Charles Anthony Dinarello1,2.   

Abstract

In this issue of Cancer Research, Wu and colleagues show that IL1b orchestrates tumor-promoting inflammation in breast cancer and can be targeted in patients using an IL1 receptor antagonist. Cancer Res; 78(18); 5200-2. ©2018 AACRSee related article by Wu et al., p. 5243. ©2018 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30217872      PMCID： PMC6242808          DOI： 10.1158/0008-5472.CAN-18-2225

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  9 in total

1.  MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study.

Authors:  Tamas Hickish; Thierry Andre; Lucjan Wyrwicz; Mark Saunders; Tomasz Sarosiek; Judit Kocsis; Radim Nemecek; Wojciech Rogowski; Krzysztof Lesniewski-Kmak; Lubos Petruzelka; Ron N Apte; Prasant Mohanty; Michael Stecher; John Simard; Aimery de Gramont
Journal:  Lancet Oncol       Date:  2017-01-14       Impact factor: 41.316

Review 2.  Why not treat human cancer with interleukin-1 blockade?

Authors:  Charles A Dinarello
Journal:  Cancer Metastasis Rev       Date:  2010-06       Impact factor: 9.264

3.  Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.

Authors:  Paul M Ridker; Jean G MacFadyen; Tom Thuren; Brendan M Everett; Peter Libby; Robert J Glynn
Journal:  Lancet       Date:  2017-08-27       Impact factor: 79.321

4.  Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma.

Authors:  John A Lust; Martha Q Lacy; Steven R Zeldenrust; Thomas E Witzig; Laurie L Moon-Tasson; Charles A Dinarello; Kathleen A Donovan
Journal:  Am J Hematol       Date:  2016-04-13       Impact factor: 10.047

5.  IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer.

Authors:  Te-Chia Wu; Kangling Xu; Jan Martinek; Robyn R Young; Romain Banchereau; Joshy George; Jacob Turner; Kyung In Kim; Sandra Zurawski; Xuan Wang; Derek Blankenship; Hannah M Brookes; Florentina Marches; Gerlinde Obermoser; Elizabeth Lavecchio; Maren K Levin; Sookyoung Bae; Cheng-Han Chung; Jennifer L Smith; Alma-Martina Cepika; Kyp L Oxley; George J Snipes; Jacques Banchereau; Virginia Pascual; Joyce O'Shaughnessy; A Karolina Palucka
Journal:  Cancer Res       Date:  2018-07-16       Impact factor: 12.701

Review 6.  Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.

Authors:  Charles A Dinarello; Anna Simon; Jos W M van der Meer
Journal:  Nat Rev Drug Discov       Date:  2012-08       Impact factor: 84.694

7.  A tumor-myeloid cell axis, mediated via the cytokines IL-1α and TSLP, promotes the progression of breast cancer.

Authors:  Emma L Kuan; Steven F Ziegler
Journal:  Nat Immunol       Date:  2018-03-19       Impact factor: 25.606

8.  Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study.

Authors:  Nicolas Isambert; Alice Hervieu; Cedric Rébé; Audrey Hennequin; Christophe Borg; Sylvie Zanetta; Angélique Chevriaux; Corentin Richard; Valentin Derangère; Emeric Limagne; Julie Blanc; Aurélie Bertaut; François Ghiringhelli
Journal:  Oncoimmunology       Date:  2018-08-01       Impact factor: 8.110

Review 9.  IL-1 and IL-1 regulatory pathways in cancer progression and therapy.

Authors:  Alberto Mantovani; Isabella Barajon; Cecilia Garlanda
Journal:  Immunol Rev       Date:  2018-01       Impact factor: 12.988
  9 in total
  6 in total

1.  Oxymatrine suppresses IL-1β-induced degradation of the nucleus pulposus cell and extracellular matrix through the TLR4/NF-κB signaling pathway.

Authors:  Kang Wei; Jun Dai; Zhenggang Wang; Yaping Pei; Yan Chen; Yifan Ding; Qing Ding; Paerxiati Ahati; Xiaozhong Zhou; Huan Wang; Huang Fang
Journal:  Exp Biol Med (Maywood)       Date:  2020-01-24

2.  Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation.

Authors:  Irena Kaplanov; Yaron Carmi; Rachel Kornetsky; Avishai Shemesh; Galina V Shurin; Michael R Shurin; Charles A Dinarello; Elena Voronov; Ron N Apte
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-13       Impact factor: 11.205

Review 3.  IL-1 Family Members in Cancer; Two Sides to Every Story.

Authors:  Kevin J Baker; Aileen Houston; Elizabeth Brint
Journal:  Front Immunol       Date:  2019-06-07       Impact factor: 7.561

4.  Assessing Tumor-Infiltrating Lymphocytes in Breast Cancer: A Proposal for Combining Immunohistochemistry and Gene Expression Analysis to Refine Scoring.

Authors:  Hanne Locy; Stefaan Verhulst; Wilfried Cools; Wim Waelput; Stefanie Brock; Louise Cras; Ann Schiettecatte; Jan Jonckheere; Leo A van Grunsven; Marian Vanhoeij; Kris Thielemans; Karine Breckpot
Journal:  Front Immunol       Date:  2022-02-11       Impact factor: 7.561

5.  IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer.

Authors:  Claudia Tulotta; Diane V Lefley; Charlotte K Moore; Ana E Amariutei; Amy R Spicer-Hadlington; Lewis A Quayle; Russell O Hughes; Khawla Ahmed; Victoria Cookson; Catherine A Evans; Jayakumar Vadakekolathu; Paul Heath; Sheila Francis; Emmanuel Pinteaux; A Graham Pockley; Penelope D Ottewell
Journal:  NPJ Breast Cancer       Date:  2021-07-21

Review 6.  Key Factor Regulating Inflammatory Microenvironment, Metastasis, and Resistance in Breast Cancer: Interleukin-1 Signaling.

Authors:  Fengjie Liu; Lihong Li; Meng Lan; Tengteng Zou; Zhaodi Kong; Tiange Cai; Xiao Yu Wu; Yu Cai
Journal:  Mediators Inflamm       Date:  2021-09-23       Impact factor: 4.711
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.